ERYtech Pharma strategy is to develop high value products, targeting hospital markets with more than one € billion potential.
ERYtech Pharma is opened to discuss partnership opportunities with pharma/biotech companies dealing with:
- its own proprietary products
- its technological platform
On technological platform, ERYtech is opened to conduct R&D feasibility study on shared cost basis which will lead to co-development agreement in case of success
A wide variety of compounds between 500 Da and up to 2000 kDa can be encapsulated.
The realization, in house, of a new proof of concept is fast and very cost effective:
- 3 to 6 months, for in vitro POC in human or mice red cells
- 6 to 9 months, for in vivo POC in mice
Co-development opportunities:
ERYtech Pharma welcomes partnership discussions on:
- Therapeutic proteins eliciting inhibitors or neutralizing antibodies or Proteins/antigens/peptides eliciting autoimmune diseases to develop Immune Tolerance Induction (Gr-Tol program)
- Antigens/adjuvants to develop active immunotherapies (Gr-Vax program)
- Compounds with anti-inflammatory properties to innovative therapeutics in the fields of inflammatory or autoimmune diseases, infectious diseases (Immuno-Inflammation application)
For more information on products and submit partnership opportunity, please send an email to busdev@erytech.com
